Metformin use is associated with longer survival in glioblastoma patients with MGMT gene silencing

Effects of Metformin as Add-On Therapy against Glioblastoma: An Old Medicine for Novel Oncology Therapeutics

(2022) Laura Guarnaccia et al.   Cancers

Metformin with Temozolomide for Newly Diagnosed Glioblastoma: Results of Phase I Study and a Brief Review of Relevant Studies

(2022) Makoto Ohno et al.   Cancers

Effect of metformin on cell proliferation, apoptosis, migration and invasion in A172 glioma cells and its mechanisms

(2019) Zhang Xiong et al.   Molecular Medicine Reports

Role of Metformin and AKT Axis Modulation in the Reversion of Hypoxia Induced TMZ-Resistance in Glioma Cells

(2019) Alessia Lo Dico et al.   Frontiers in Oncology

OUP accepted manuscript

(2018)   JNCI-Journal of the National Cancer Institute

Dose-Dependent Relationship Between Metformin and Colorectal Cancer Occurrence Among Patients with Type 2 Diabetes—A Nationwide Cohort Study

(2018) Yu-Tang Chang et al.   Translational Oncology

OUP accepted manuscript

(2018)   JNCI-Journal of the National Cancer Institute

A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913

(2017) Prakash Chinnaiyan et al.   NEURO-ONCOLOGY

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma

(2017) James R. Perry et al.   NEW ENGLAND JOURNAL OF MEDICINE

Metformin and temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models

(2017) Silvia Valtorta et al.   Oncotarget

Metformin for cancer prevention: a reason for optimism

(2016) Andrew T Chan   LANCET ONCOLOGY

Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial

(2015) Sil Kordes et al.   LANCET ONCOLOGY

Metformin Inhibits Growth of Human Glioblastoma Cells and Enhances Therapeutic Response

(2015) Julie Sesen et al.   PLoS One

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

(2014) Mark R. Gilbert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide

(2014) Krzysztof Łabuzek et al.   Pharmacological Reports

IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives

(2012) H. Yang et al.   CLINICAL CANCER RESEARCH

IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas

(2012) Tareq A. Juratli et al.   JOURNAL OF NEURO-ONCOLOGY

Glioma-Initiating Cell Elimination by Metformin Activation of FOXO3 via AMPK

(2012) Atsushi Sato et al.   Stem Cells Translational Medicine

Comprehensive Analysis of MGMT Promoter Methylation: Correlation with MGMT Expression and Clinical Response in GBM

(2011) Nameeta Shah et al.   PLoS One

High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2010) R. Stupp et al.   ANNALS OF ONCOLOGY

In vivo assessment of high-grade glioma biochemistry using microdialysis: a study of energy-related molecules, growth factors and cytokines

(2009) Hani J. Marcus et al.   JOURNAL OF NEURO-ONCOLOGY

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2008) D. M. Nathan et al.   DIABETES CARE

Dose translation from animal to human studies revisited

(2007) Shannon Reagan-Shaw et al.   FASEB JOURNAL